Rituximab dosing in hematological malignancies: an old question, revisited

AbstractRituximab is the standard of care for most B-cell malignancies. Its rapid clinical development enabled patients to receive this life-prolonging medicine sooner; however, it precluded a thorough assessment of dose selection. Extensive clinical pharmacology data collected from the recent subcutaneous development program enabled re-examination of this old question and support that the approved rituximab dosing regimens in non-Hodgkin ’s lymphoma and chronic lymphocytic leukemia appear to maximize the clinical benefit in the majority of patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research